The global dental bone graft and substitutes market by Product Type (Demineralized Bone Matrix (DBM), Allograft, Xenograft, and Synthetic Bone Graft Substitutes), by Material Type (Collagen, Human Cell Source, Animal Source, Hydroxyapatite (Ha), Tricalcium Phosphate (TCP), and Others), by End User (Hospitals, Clinics, and Ambulatory Surgery Centers), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 418.4 million in 2016 and is projected to exhibit a CAGR of 9.1% over the forecast period (2017–2025).
Improvements in grafting materials and development of novel bone graft substitutes such as bone morphogenic proteins, along with increasing use of autografts is expected to fuel growth of the dental bone graft and substitutes market over the forecast period. Continuous research and development in graft material along with improvement in bone grafting procedures are factors expected to aid in growth of the market. Manufacturers are focusing on launching new bone grafting products and related systems and accessories in order to cater to changing needs of the market. In 2015, NovaBone Product LLC received the U.S. Food & Drug Administration approval for launching minimally invasive bone graft system — NovaBone MacroFORM MIS delivery system — designed specifically for minimally invasive orthopedic procedures. In January 2017, Citagenix, Inc. — subsidiary of Antibe Therapeutics Inc. — launched PentOS OI Max for oral and maxillofacial surgery. In 2016, Glidewell Laboratories launched a new line of dental bone grafting products under the brand, Newport Biologics. The line consists allograft and alloplast bone grafts. Furthermore, MIS Implant Technologies launched its bone graft cement 4MATRIX in 2016. The product was developed to simplify dental bone grafting procedures for dental prosthetic solutions and implants.
Browse 40 Market Data Tables and 36 Figures spread through 150 Pages and in-depth TOC on Dental Bone Graft and Substitutes Market by Product Type (demineralized bone matrix (DBM), Allograft, Xenograft, and Synthetic Bone Graft Substitutes), by Material Type (collagen, human cell source, animal source, hydroxyapatite (HA), tricalcium phosphate (TCP) and others), by End User (hospitals, clinics, and ambulatory surgery centers), and Region (North America, Latin America, Europe, Asia-Pacific, the Middle East, and, Africa) - Global Forecast to 2025.
To know the latest trends and insights prevalent in the dental bone graft and substitutes market, click the link below: https://www.coherentmarketinsights.com/market-insight/dental-bone-graft-and-substitutes-market-1187
Dental bone grafting procedures are introduced to simplify surgical procedures and to reduce peri-operative and post-operative complications. For instance, in November 2017, a team of researchers from University of Minnesota introduced Continuous Periosteal Strapping Suture (CPSS) technique, which depends on resorbable sutures and membranes to maintain the integrity of the dental bone graft eliminating the requirement of an additional surgery for removal of tenting screws or tacks. Furthermore, research in bioactive glass for bone grafting is also aiding in growth of the market. For instance, in 2016, engineers from Oregon State University (OSU) conducted research and reported potential effects of bioactive glass, which can reduce bacterial tendency of attacking tooth fillings. According to a study published in 2013, in Journal of Oral Implantology — an official publication of American Academy of Implant Dentistry — a new acellular dermis matrix (ADM) replacement material, decellularized dermis matrix (DDM) coupled with mineralized cancellous bone allograft (MCAB), can guide the regeneration of bone causing stable placement of the implant.
Key Takeaways of the Dental Bone Graft and Substitutes Market:
Some major players operating in the dental bone graft and substitutes market include Institut Straumann AG, Geistlich, DENTSPLY International, Zimmer Biomet, Medtronic Plc., BioHorizons IPH, Inc., ACE Surgical Supply Company, Inc., RTI Surgical, Inc., LifeNet Health, and Citagenix.